Cannabidiol is available on the market in various forms, from oils, vapes, creams, gummies, drinks and much more. Until now, several studies reported the potential of this substance for treating chronic pain.
But a group of researchers from the UK and Canada decided to do an extensive literature review and cross-reference the results of all these studies.
The aim was to see whether this substance, present in the cannabis plant, has the potential to be used as a therapeutic strategy.
However, the results have not been the most satisfactory, at least for the brands that sell these products.
Apparently, there is not enough scientific evidence to conclude that CBD can have clinical applicability, according to the study published in The Journal of Pain.
In view of these conclusions, the scientists are warning the authorities that the various marketing strategies used to market CBD products are dangerous. They claim that science was still studying the potential benefits of this substance when its promotion on the market took off in full swing.
"It is well known that chronic pain, when left untreated, seriously impairs quality of life. Unfortunately, there are still many people who live with this condition on a daily basis," explains Chris Eccleston, author of the study and researcher at the University of Bath.
"Pain deserves scientific investment in order to find effective solutions," he added in a statement issued by the University of Bath.
